Patient characteristics, persistence to treatment and outcome events in patients treated with ticagrelor 60 mg after myocardial infarction in real-world clinical practice

Trial Identifier: D5130R00057
Sponsor: AstraZeneca
NCTID:: NCT04568083
Start Date: September 2020
Primary Completion Date: June 2021
Study Completion Date: June 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Wismar, Germany
Italy Rome, Italy
Sweden Stockholm, Sweden
United Kingdom London, United Kingdom
United States of America, MA Waltham, MA, United States of America, 02451
United States of America, MD Bethesda, MD, United States of America, 20814